InspireMD, Inc. (NSPR) Cash Flow Statement

NASDAQ: NSPROperating cash, capex, free cash flow and buybacks.

Where NSPR’s cash came from and went, 2025

December 31, 2025 · U.S. dollars
Cash from operations
−$35.1M
Capital expenditures
$1.7M
18.5% of revenue
Free cash flow
−$36.8M
−409.5% margin
Returned to shareholders
—
Change in cash
−$10.0M
cash at year-end $8.9M
Shares issued: $38.7MShares issued$38.7MOther financing: $16.9MOther financing$16.9MDrawn from cash: $10.0MDrawn from cash$10.0MAcquisitions & other: $294,000Acquisitions & other$294,000Cash used in operations: $35.1MCash used in operations$35.1M · 53%Investments (net): $29.2MInvestments (net)$29.2M · 44%Capital expenditures: $1.7MCapital expenditures$1.7M · 3%$66.0M
Cash from operations
−$35.1M
Capital expenditures
−$1.7M
Investments (net)
−$29.2M
Acquisitions & other
+$294,000
Shares issued
+$38.7M
Other financing
+$16.9M
Change in cash
−$10.0M

Drawn to scale: where the cash came from and how it was used. Hover for values.

NSPR operating cash flow, capex and free cash flow

Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)

NSPR cash flow trends, 2016–2025

InspireMD, Inc. cash flow trends
MetricTrendThenLatestChange
Operating cash flow−$7.5M2016−$35.1M2025—
Capital expenditures$49,0002016$1.7M2025+47.9%/yr
Free cash flow−$7.5M2016−$36.8M2025—
Free cash flow margin−398.3%2016−409.5%2025−11.1 pts
Stock-based compensation$978,0002016$12.3M2025+32.5%/yr
Dividends paid$02016$02017—
Share buybacks (net)$14,0002016$02020−100.0%
Capex / revenue2.6%201618.5%2025+15.9 pts

Change is the average annual growth (CAGR) or the difference between the first and latest year.

NSPR cash flow by activity

OperatingInvestingFinancingChange in cash

NSPR net income vs operating cash flow

Net incomeOperating cash flow

Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).

NSPR cash flow statement

InspireMD, Inc. annual cash flow statement
2025202420232022202120202019201820172016
Operating activities
Net income−$48.8M−$32.0M−$19.9M−$18.5M−$14.9M−$10.5M−$10.0M−$7.2M−$8.4M−$8.5M
Depreciation & amortization$476,000$280,000$232,000$188,000$161,000$151,000$158,000$152,000$178,000$191,000
Stock-based compensation$12.3M$10.1M$4.5M$2.4M$1.6M$606,000$325,000$70,000$672,000$978,000
Change in working capital$1.1M$736,000−$801,000$395,000−$75,000$533,000−$350,000−$182,000−$60,000−$290,000
Other non-cash items−$231,000−$1.0M−$381,000$14,000$46,000$173,000$97,000−$406,000−$483,000$87,000
Cash from operating activities−$35.1M−$21.9M−$16.4M−$15.5M−$13.2M−$9.1M−$9.8M−$7.6M−$8.1M−$7.5M
Investing activities
Capital expenditures−$1.7M−$1.4M−$381,000−$473,000−$344,000−$88,000−$284,000−$67,000−$258,000−$49,000
Investments (net)−$29.2M$12.6M−$16.1M$8.4M−$22.0M−$187,000−$387,000−$44,000−$318,000$70,000
Acquisitions & other investing$294,000$1.4M$381,000$473,000−$113,000$88,000$284,000$67,000$258,000$49,000
Cash from investing activities−$30.6M$12.6M−$16.1M$8.4M−$22.5M−$187,000−$387,000−$44,000−$318,000$70,000
Financing activities
Dividends paid————————$0$0
Share repurchases & issuance (net)—————$16.4M$6.3M−$3.0M−$10,000−$14,000
Net borrowing (repayment)————————−$2.2M−$2.6M
Shares issued$38.7M$1.6M$37.5M$37.5M$35.0M$16.4M$6.3M$16.4M$0$0
Other financing$16.9M$16.9M$0−$37.7M$0−$16.4M−$6.3M$0$6.8M$14.4M
Cash from financing activities$55.6M$18.5M$37.5M−$140,000$35.0M$16.4M$6.3M$13.4M$4.6M$11.7M
Summary
Net change in cash−$10.0M$9.3M$5.0M−$7.4M−$641,000$7.1M−$3.9M$5.7M−$3.8M$4.3M
Cash at end of period$8.9M$18.9M$9.6M$4.6M$12.0M$12.6M$5.5M$9.4M$3.7M$7.5M
Free cash flow−$36.8M−$23.3M−$16.8M−$16.0M−$13.6M−$9.2M−$10.1M−$7.7M−$8.4M−$7.5M
Free cash flow margin−409.5%−332.0%−270.1%−309.7%−301.5%−369.0%−271.3%−213.1%−303.8%−398.3%
Capex / revenue18.5%20.0%6.1%9.1%7.7%3.5%7.6%1.9%9.3%2.6%

Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.

NSPR cash generation

In fiscal 2025 (ended December 31, 2025), InspireMD generated -$35.1 million of cash from operations and spent $1.7 million on capital expenditures, leaving free cash flow of -$36.8 million, −409.5% of revenue. Cash and equivalents fell by $10.0 million over the year.

Related: NSPR income statement, NSPR balance sheet. See the NSPR stock overview for the latest quote and news.

NSPR cash flow FAQ

What is InspireMD's free cash flow?

InspireMD's free cash flow was -$36.8 million in fiscal 2025: -$35.1 million of operating cash flow minus $1.7 million of capital expenditures It was -$23.3 million a year earlier..

How much cash does InspireMD generate from operations?

InspireMD generated -$35.1 million of cash from operating activities in fiscal 2025.

How much does InspireMD spend on capital expenditures?

InspireMD spent $1.7 million on capital expenditures in fiscal 2025, 18.5% of revenue, compared with $1.4 million the year before.

Medical Devices: cash flow